NWBO could issue 900 Million shares to raise capital and avoid being bought out by a big pharmaceutical corporation. Why would NWBO not sell all of its authorized shares during a short-squeeze for around $5/share?
I understand that the August 2015 FDA partial hold on the Phase 3 Study for DCVax-L was first disclosed by AVII77, and that NWBO published its 80/21/2015 Form 8-K disclosing the hold in response to this leak by AVII77. Is that true?
In other words, you have no evidence that NICE Technology Advisory Committee B will be discussing DCVax-L at their upcoming January 14, 2026 meeting. Correct?
Flipper 44 reports that NICE Technical Advisory Committee B will be considering DCVax-L at its January 14, 2026 meeting. Is there any evidence that this is true?
It is not true that publicly-traded companies seek an increase in authorized shares shortly before an anticipated positive result in a binary event. NWBO would be in a much stronger position to ask for this authority from its shareholders after a positive response from the MHRA. I will vote no unless we get a positive response from the MHRA before the 2025 all shareholders' meeting.